CONCISE REPORT

Definition of disease duration in ankylosing spondylitis: reassessing the concept

J C Davis¹, M Dougados², J Braun³, J Sieper⁴, D van der Heijde⁵, S van der Linden⁵

¹ Division of Rheumatology, University of California San Francisco, San Francisco, California, USA
² Rheumatology B Department, Hospital Cochin, University of Paris, Paris, France
³ Rheumatology Medical Center Ruhrgebiet, Herne, Germany
⁴ Department of Medicine I, Charite-Campus Benjamin Franklin, Berlin, Germany
⁵ Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands

Correspondence to:
S van der Linden
Department of Internal Medicine, Division of Rheumatology, University of Maastricht, PO Box 5800, NL-6202-AZ Maastricht, The Netherlands; Sli{at}sint.azm.nl

The concept and definition of disease duration in patients with ankylosing spondylitis is ambiguous, and often many years pass between the onset of symptoms and diagnosis. Members of the Assessment in Ankylosing Spondylitis (ASAS) International Working Group by consensus recently recommended identifying specific components of the medical history to better define and document the concept of disease duration. These include (1) the time of onset of the first symptoms of axial manifestations (including inflammatory back pain); (2) the time of onset of the first symptoms of each individual manifestation, which may be an extra-axial sign or symptom of ankylosing spondylitis, such as peripheral arthritis and enthesitis; (3) the time of onset of associated diseases belonging to the spondyloarthritides, in particular acute anterior uveitis, inflammatory bowel disease and psoriasis; and (4) the time since actual diagnosis by a healthcare provider. Such uniformity in data collection will ensure comparability across studies and facilitate future research.

Abbreviations: AAU, acute anterior uveitis; ASAS, Assessment in Ankylosing Spondylitis; IBD, inflammatory bowel disease; SpA, spondyloarthritides

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• RUDWALEIT, M., CLAUDEPIERRE, P., WORDSWORTH, P., CORTINA, E. L., SIEPER, J., KRON, M., CARCERERI-DE-PRATI, R., KUPPER, H., KARY, S. (2009). Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis. The Journal of Rheumatology 36: 801-808 [Abstract] [Full Text]  
• Rojas-Vargas, M., Munoz-Gomariz, E., Escudero, A., Font, P., Zarco, P., Almodovar, R., Gratacos, J., Mulero, J., Juanola, X., Montilla, C., Moreno, E., Collantes-Estevez, E., on behalf of REGISPONSER working group, (2009). First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatology (Oxford) 48: 404-409 [Abstract] [Full Text]